Business Case

Evaluated Ischemic Heart Failure Commercial Opportunity to Guide Portfolio Investment Decisions at a Mid-Size Biotech

Our client was a clinical-stage, mid-size gene therapy manufacturer looking to further deploy its technology and target additional therapies in the heart failure space. LSC was tasked with developing a portfolio investment strategy that would maximize the opportunity of limited R&D resources. LSC was able to evaluate and prepare a report on the heart failure market landscape, identify and evaluate specific opportunities and ultimately use a mix of quantitative and qualitative approaches to form investment recommendations for our client, which has been able to successfully initiate several clinical programs based on the results of LSC’s analysis.